HighVista Strategies’s CytomX Therapeutics CTMX Stock Holding History

HighVista Strategies’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$637K	Sell	169,831 -118,226	-41%	-$451K	0.15%	138
2026 Q1	$1.35M	Buy	288,057 +94,116	+49%	+$478K	0.37%	86
2025 Q4	$826K	Sell	193,941 -63,207	-25%	-$240K	0.21%	118
2025 Q3	$820K	Buy	+257,148	New	+$579K	0.2%	131
2020 Q4	–	Sell	-13,000	Closed	-$86K	–	121
2020 Q3	$86K	Buy	+13,000	New	+$96.4K	0.06%	86
2020 Q1	–	Sell	-13,900	Closed	-$116K	–	84
2019 Q4	$116K	Buy	+13,900	New	+$93.8K	0.09%	77

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

HighVista Strategies's CTMX Position: Q2 2026 in Review

HighVista Strategies reduced its CytomX Therapeutics (CTMX) stake by 41% in Q2 2026, selling an estimated $451K and leaving 169,831 shares worth $637K. The position accounts for 0.15% of the portfolio, ranked #138.

HighVista Strategies first reported a position in CTMX in Q4 2019 and has held it in 6 quarters since. The position peaked at $1.35M in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

HighVista Strategies held 169,831 shares of CytomX Therapeutics worth $637K as of Q2 2026.
HighVista Strategies sold 118,226 CytomX Therapeutics shares in Q2 2026, an estimated $451K.
CytomX Therapeutics made up 0.15% of HighVista Strategies's portfolio in Q2 2026, its #138 holding.
HighVista Strategies first reported a position in CytomX Therapeutics in Q4 2019 and has held it in 6 quarters since.
HighVista Strategies's CytomX Therapeutics position peaked at $1.35M in Q1 2026.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.